Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC
The program was brought together to discuss immunotherapy options for non–clear cell RCC in light of emerging clinical trial data and NCCN guidelines.
Related Articles
Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL
Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Down with dex!
In this issue of Blood, Banerjee et al1 present a secondary analysis of pooled data from 2 completed SWOG cooperative group trials (SO777 and S1211), showi
2024 ARC Amyloidosis Community Survey
ARC is conducting an online survey of patients and caregivers for individuals living with amyloidosis to collect data and information on …
Program: Wednesday, February 26
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
Patient-Matched Tumor-Normal Sequencing
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build…
What will Trump’s return to the White House mean for oncology? “Our work just got a lot more difficult.” – The Cancer Letter
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in…
Racial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992–2021
Testicular cancer age-standardized incidence rates per 100,000 person-years increased from 4.71 (95% confidence interval, 4.39–5.05) in 1992 to 6.22 (95% confidence interval, 5.88–6.58) in 2021,…
$80K Sign-on Bonus- $20k Fellowship Stipend at Schneck Medical Center
Hospital Employed, President/CEO is a Physician $80k Sign-On Bonus + $20k Fellowship Stipend 4 day work week New physician will see patients from existing patient…
Epcoritamab Is Associated With Higher Travel Burden/Costs in R/R DLBCL and Follicular Lymphoma
Zachary Frosch, MD, MSHP, discusses the investigation of travel burden/costs related to bispecific antibodies in diffuse large B-cell lymphoma or follicular lymphoma.
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.